Citations

Clear

16280 citation(s) found for "Yu, David".

Cerebellum mitochondrial DNA copy number is increased in Parkinson’s disease
Beglarian, Talia , Tyrpak, David R. , MacKay, J. Andrew , Scholz, Sonja W. , Albert, Marilyn S. , Dawson, Ted M. , Troncoso, Juan C. , Hernandez, Dena G., Cookson, Mark R , Singleton, Andrew B., Beach, Thomas G., Hjelm, Brooke E. , MacKay, John Andrew , Scholz, Sonja W , Dawson, Ted M , Cookson, Mark , Adler, C H , Serrano, Geidy E , Hjelm, Brooke E , Gibbs, J. Raphael , Traynor, Bryan J , Rosenthal, Liana S. , Adler, Charles H. , Serrano, Geidy E. , Singleton, Andrew B., Beach, Thomas G.

Mayo Clinic

Brain Communications | August 20, 2025 | Volume: 7 | Issue: 4 | Pages: No page available

10.1093/braincomms/fcaf296 | PMID 40873892 Get It

Abstract Bioinformatics methods can be used to quantify mitochondrial DNA copy number from whole genome sequencing (WGS) data. We evaluated mitochondrial DNA copy number from human brain-derived WGS data using the fastMitoCalc tool. 341 Parkinson’s Disease cerebellum samples were compared with 74 age-matched controls from the North American Brain Expression Consortium. Parkinson’s Disease cerebellum had significantly higher mitochondrial DNA copy number compared with controls (P = 4.15e–7), and this effect was reproducible in four of five brain banks when analysis was restricted to each resource that contributed Parkinson’s Disease samples to this genetic dataset. Follow-on analyses of 128 Parkinson’s Disease cerebellum samples and 33 controls that had paired neuropathology data and clinical scores demonstrated a significant increase in mitochondrial DNA copy number with Unified Staging System for Lewy Body disorders stages and Unified Parkinson’s Disease Rating Scale (off meds) motor scores. Analysis of Lewy Body scores from ten brain regions showed cerebellum mitochondrial DNA copy number increased upon pathological infestation of α-synuclein aggregates in the brainstem and limbic system but did not increase after late-stage neocortical involvement. This genetics dataset supports previous observations of cerebellum activation in Parkinson’s Disease and suggests mitochondrial DNA copy number may increase to support this regional activation as a compensatory mechanism to pathology or motor symptoms.
Relationship Between Diurnal Variations of Episcleral Venous Pressure and Intraocular Pressure
Kazemi, Arash , Chowdhury, Uttio Roy, Fautsch, Michael P. , Htoo, Thurein M., Wirostko, Barbara, Hodge, David O. , Sit, Arthur J. , Sit, Arthur J

Mayo Clinic

Investigative Ophthalmology & Visual Science | August 19, 2025 | Volume: 66 | Issue: 11 | Pages: 44

10.1167/iovs.66.11.44 | PMID 40828522 Get It

Detection, quantitation, and genotyping of human papillomavirus circulating tumor DNA by droplet digital PCR
Fernholz, Emily C. , Abel, Kathryn M. Van , Moore, Eric J. , Daniel, Jeannie, Hunter, Danielle E., Lewis, James S. , Wendlandt, Erik, Binnicker, Matthew J. , Bartemes, Kathleen R. , Binnicker, Matthew J , Van Abel, Kathryn M , Routman, David M. , Ma, Daniel J.

Mayo Clinic

Journal of Clinical Microbiology | August 19, 2025 | Volume: 63 | Issue: 9 | Pages: No page available

10.1128/jcm.00585-25 | PMID 40827899 Get It

ABSTRACT Human papillomavirus (HPV) is comprised of >200 genotypes and has an ~8 kb, circular, double-stranded DNA genome. Transmission of HPV occurs through skin-to-skin contact and infection of squamous epithelial cells of cutaneous and mucosal surfaces. HPV genotypes are categorized as low- or high-risk (hrHPV) based on oncogenic potential. There are approximately 14 types of hrHPV that can cause several types of cancer, including HPV-associated oropharyngeal squamous cell carcinoma (HPV(+)OPSCC). Detection of HPV(+)OPSCC is traditionally accomplished using p16 immunohistochemistry (IHC) and HPV-specific testing, either DNA or RNA in situ hybridization (ISH) staining or DNA-based PCR of suspected tumor biopsy tissue. More recently, platelet-poor plasma (PPP) samples from patients with HPV(+)OPSCC have proven useful for detection and quantitation of fragments of HPV circulating tumor DNA (ctDNA). ctDNA has been shown to be useful in determining treatment response and monitoring for disease recurrence. In this study, a novel droplet digital PCR assay (ddPCR) was developed and validated for the detection and quantitation of ctDNA from 5 hrHPV genotypes in PPP. Analytical sensitivity ranged from 7.71 to 19.45 fragments of HPV ctDNA per milliliter of PPP across five hrHPV genotypes. In patients with confirmed primary or recurrent HPV(+)OPSCC or HPV(-)OPSCC, testing of corresponding PPP samples ( n = 32) by ddPCR demonstrated 90.63% (29/32) overall agreement with p16/HPV-ISH biopsy results. Compared with reference ddPCR assays performed at outside laboratories, our ddPCR assay yielded 90% (9/10) overall agreement. This assay may provide clinicians with a tool for monitoring HPV ctDNA prior to, during, and after treatment of an HPV-associated cancer. IMPORTANCE At least 14 genotypes of human papillomavirus (HPV) have been identified to have high oncogenic potential. While molecular diagnostic testing for HPV is widely available for liquid cytologic cervical samples, testing is limited for other sample types, including liquid biopsy samples, such as platelet-poor plasma (PPP). With the rising incidence of HPV-associated oropharyngeal squamous cell carcinoma (HPV(+)OPSCC), laboratory testing is an essential part of patient diagnosis, management, and surveillance. Here, we summarize the development and analytical performance validation of a multiplexed, droplet digital PCR (ddPCR) assay for the detection and quantitation of HPV circulating tumor DNA (ctDNA) in PPP. This assay may provide clinicians with a tool to address minimal residual disease for patients with an HPV-associated cancer.
Disseminated Varicella-Zoster Virus Infection with Internal Organ Involvement: A Scoping Review of 156 Cases
Timotijevic, Aleksandar, Kodela, Pratyusha , Glušac, Vladislav, Bokonjic, Sara , Joksimović, Bojan , Gomez, Juan Vera, Ladin, David, Dumic, Igor , Vera Gomez, Juan, Dumic, Igor , Joksimović, Bojan , Gomez, Juan Vera, Ladin, David

Mayo Clinic

Viruses | August 19, 2025 | Volume: 17 | Issue: 8 | Pages: 1135

10.3390/v17081135 | PMID 40872848 Get It

Visceral disseminated varicella-zoster virus infection (VD-VZV) involves the hematogenous spread of VZV from the skin to the internal organs. Though rare, it is potentially life-threatening, predominantly affecting immunocompromised individuals. Diagnosis is often delayed due to nonspecific symptoms mimicking other viral illnesses. While the vesicular rash is a hallmark sign, it is absent in approximately 5% of cases. Visceral involvement may precede cutaneous lesions, complicate early recognition, and increase the risk of severe complications. This scoping review screened 594 articles of which 153 met the inclusion criteria, yielding 156 individual cases. Patients were predominantly male (53.8%), with a mean age of 42.3 years. The overall mortality rate was 25.0%. Multiple organs were involved in 46.1% of cases. The most frequently affected were the lungs (56%), liver (44%), heart (16%), kidneys (11%), pancreas (11%), stomach (10%), and esophagus (6%). Antivirals were administered in 89.1% of cases, while corticosteroids were used in 22.4%, with no significant impact on outcomes. Early diagnosis, achieved in 65.4% of patients, was significantly associated with survival (p = 0.043). Mortality was significantly associated with underlying comorbidities (p = 0.004), especially autoimmune diseases requiring immunosuppression (p = 0.048). Septic shock or multi-organ dysfunction (MODS), hepatitis, acute kidney injury, and acute liver failure were linked to higher mortality in univariate analysis. Multivariate analysis identified comorbidities (p < 0.001), septic shock/MODS (p = 0.008), and acute liver failure (p = 0.039) as independent predictors of mortality. Patients with septic shock/MODS had over twice the risk of death (OR = 2.24; p = 0.008). This review underscores the diagnostic challenges and high mortality of VD-VZV. Early recognition and timely administration of antiviral treatment appear critical for survival. Greater clinical awareness and further research are needed to guide management.
18 F‐FDG PET in detection of primary age‐related tauopathy (PART) – Is there a role? Insights from an imaging‐pathology correlation study
Pham, Nha Trang Thu, Vernon, Cynthia J. , Graff‐Radford, Jonathan, Knopman, David S. , Kantarci, Kejal , Jack, Clifford R. , Ross, Reichard R., Petersen, Ronald C. , Lowe, Val J. , Whitwell, Jennifer L. , Josephs, Keith A. , Jack, Clifford R , Kantarci, Kejal , Lavrova, Anna , Graff‐Radford, Jonathan , Boeve, Bradley F. , Knopman, David S. , Nguyen, Aivi T. , Ross, Reichard R., Dickson, Dennis W.

Mayo Clinic

Alzheimer's & Dementia | August 19, 2025 | Volume: 21 | Issue: 8 | Pages: No page available

10.1002/alz.70568 | PMID 40827317 Get It

Abstract INTRODUCTION Primary age‐related tauopathy (PART) is defined by neurofibrillary tangles (NFTs) with absent‐minimal amyloid beta (Aβ) plaques. Currently, definitive diagnosis of PART occurs with autopsy. This study investigated whether [ 18 F]fluorodeoxyglucose positron emission tomography (FDG‐PET) could detect PART‐related metabolic changes and assessed the impact of common co‐pathologies. METHODS We performed a retrospective cross‐sectional study of 88 individuals (mean age 85.6) with autopsy‐confirmed PART (Braak I to IV; Thal phases 0 to 2) who underwent ante mortem FDG‐PET. Visual ratings and standardized uptake value ratios (SUVRs) were analyzed in medial and lateral temporal lobes, inferior temporal pole, precuneus, and posterior cingulate regions. RESULTS Medial temporal hypometabolism was observed in PART, in the presence of co‐pathologies. Argyrophilic grain disease and TAR DNA‐binding protein 43 were associated with greater hypometabolism ( p < 0.01). Lewy body disease affected parietal regions. DISCUSSION FDG‐PET reveals that PART‐related hypometabolism occurs when co‐pathologies are present, but PART alone appears to have minimal effect on medial temporal lobe hypometabolism. Highlights FDG‐PET hypometabolism worsens with Braak NFT stage. FDG‐PET detects mild lateral temporal lobe hypometabolism in PART alone. PART alone has a minimal effect on medial temporal lobe hypometabolism. Medial temporal hypometabolism is worse in PART with TDP‐43 and especially AGD. The presence of LBD contributes to parietal hypometabolism on FGD‐PET in PART.
Long-Term Survival After Surgical Resection for Rectal Cancer Is Associated With Textbook Outcome but Not Surgical Case Volume
Aly, Mohamed R., Stucky, Chee-Chee, Etzioni, David A. , Wasif, Nabil , Etzioni, David, Chang, Yu‐Hui , Fong, Zhi Ven

Mayo Clinic

Annals of Surgery Open | August 18, 2025 | Volume: 6 | Issue: 3 | Pages: e601

10.1097/as9.0000000000000601 | PMID 40989869 Get It

Objective: Analyzing textbook outcome (TO) following rectal cancer resection and its association with long-term survival when compared to hospital case volume alone. Background: TO is a quality metric representing the ideal result following complex cancer surgery. Prior studies have suggested improved long-term survival for rectal cancer patients undergoing surgery at HV institutions. Methods: Patients undergoing surgery for rectal adenocarcinoma from 2014 to 2015 were identified using the National Cancer Database. Low (LV), medium (MV), and high-volume (HV) hospital strata were defined by quartile cutoffs (low <25th, high >75th, and 25–75th medium volume). TO was achieved with adequate lymph node count (≥12), negative margins (R0 resection), length of stay <75th percentile, absence of 30-day readmission/mortality event, and appropriate plus timely systemic therapy. Adjusted analyses for long-term survival were performed using a hierarchical multivariable Cox regression model. Results: TO was achieved in 28.5% of 48,484 patients. LV or MV hospital patients were more likely to be older, uninsured/Medicaid, and less likely to achieve a TO (HV 31.2% vs MV 29.6% vs LV 23.2%, P < 0.001). TO was associated with improved 5-year survival (84.0% vs 72.0%, P < 0.001). On multivariable analyses, TO was the strongest protective factor against mortality (HR 0.60, 95% confidence interval = 0.56–0.64), even after controlling for case volume. Conclusions: Only 28.5% of patients undergoing resection for rectal cancer achieve TO. However, they had a 40% reduction in long-term mortality independent of hospital volume. Optimizing long-term survival in patients with rectal cancer can be achieved by TO criteria rather than increasing surgical case volume.
Injury epidemiology in young female American football athletes: a 10-year analysis using NEISS data
Sugimoto, Dai , Schultz, Cassidy , Radel, Luke C. , Soma, David , Ulman, Sophia , Jones, Jacob C. , Schultz, Cassidy , Radel, Luke, Ulman, Sophia , Jones, Jacob , Mikhail, David

Mayo Clinic

The Physician and Sportsmedicine | August 18, 2025 | Volume: 53 | Issue: 6 | Pages: 441-447

10.1080/00913847.2025.2548761 | PMID 40823944 Get It

Treg-specific IL-6R signaling: a novel role in the regulation of the intestinal epithelium
Klatt, Emily, Hamdan, Feda H. , Pérez, Isaiah , Kossick, Kimberlee , Fedyshyn, Yaroslav , Sagstetter, Mary R., Chiang, David , Chini, Lucas C. S., Davidson, H, Westphal, Maria S., Gades, Naomi M. , Mopuri, Rohini , Druliner, Brooke R. , Faubion, William A. , Klatt, Emily E, Smith, Hannah M , Kossick, Kimberlee , Davidson, Heidi M, Bamidele, Adebowale O , Druliner, Brooke , Chini, Lucas C. S., Sun, Zhifu , Bamidele, Adebowale O.

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | August 18, 2025 | Volume: 329 | Issue: 6 | Pages: G696-G707

10.1152/ajpgi.00131.2025 | PMID 40820933 Get It

This study reveals a novel role for Treg-derived IL-6R in supporting epithelial repair. Despite preserved immune-suppressive capacity, deletion of IL-6R from Tregs impairs epithelial transcription and worsens injury in colitis. We demonstrate that human intestinal organoids preferentially respond to trans- over classic IL-6 signaling. These findings introduce a Treg-specific role in immune-epithelial cross talk relevant to mucosal healing and inflammatory bowel disease.
Resmetirom in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis
Jamal, Fares , Elshaer, Amani , Odeh, Nour B., Alatout, Mayar H., Shahin, Tala, Worden, Astin R., Albunni, Hashem , Jayasekera, Channa R. , Chascsa, David M. , Vargas, Hugo E. , Aqel, Bashar , Albunni, Hashem N , Lizaola-Mayo, Blanca C, Jayasekera, Channa R , Chascsa, David M H, Aqel, Bashar A. , Vargas, Hugo E , Jamal, Fares , Lizaola‐Mayo, Blanca

Mayo Clinic

Life | August 18, 2025 | Volume: 15 | Issue: 8 | Pages: 1306

10.3390/life15081306 | PMID 40868953 Get It

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), are among the most prevalent causes of chronic liver disease worldwide, closely linked to the global rise in overweight and obesity, type 2 diabetes, and metabolic syndrome. Until recently, treatment options were limited to lifestyle interventions, with no approved pharmacologic therapies. Resmetirom, a liver-directed, selective thyroid hormone receptor beta (THR-β) agonist, is a promising disease-modifying agent that targets hepatic lipid metabolism, inflammation, and fibrosis. Clinical trials, including the pivotal phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 trials, have demonstrated significant improvements in liver fat reduction, lipid profiles, histological endpoints, and health-related quality of life, with a favorable safety profile. In March 2024, the FDA granted accelerated approval of resmetirom for adults with MASH and moderate-to-advanced fibrosis, marking a significant milestone in MASLD treatment. This review discusses the mechanistic rationale, preclinical data, and pivotal clinical trial outcomes supporting resmetirom’s role in MASLD/MASH management, while outlining ongoing research needs, including long-term safety, pediatric evaluation, and biomarker development for optimized patient selection.
Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines for the Role of Radiosurgery for Patients With Functioning Pituitary Adenomas
Green, Sheryl , Lehrer, Eric J. , Sheehan, Jason , Cifarelli, Christopher P. , Recinos, Pablo F. , Ziu, Mateo , Ormond, David Ryan , Germano, Isabelle M.

Mayo Clinic

Neurosurgery | August 15, 2025 | Volume: 97 | Issue: 3S | Pages: S36-S43

10.1227/neu.0000000000003582 | PMID 40815129 Get It

BACKGROUND: Patients with functioning pituitary adenomas (FPA) require a multidisciplinary team-based approach to select best medical, surgical, and radiation treatments, including stereotactic radiosurgery (SRS). OBJECTIVE: The aim of this study was to provide evidence-based recommendations on the use of SRS for adult patients with FPA. METHODS: PubMed and Embase were searched from data base inception to June 8, 2021. Full-text articles were then screened using published exclusion/inclusion criteria. Evidence tables were developing based on data extraction from the full-text reviews, and evidence-based recommendations were finalized. RESULTS: Of the total 1842 abstracts pertinent to this topic, 343 full articles met eligibility. Of these, 21 met entry criteria and were included in the evidence tables. The provided Class III evidence supported 2 Level III recommendations: 1. SRS, hypofractionated SRS, fractionated (>5 fractions) radiotherapy, and conventional radiation therapy provide excellent radiographic control with variable hormonal reduction and endocrine remission rates. For SRS and fractionated radiotherapy hormonal reduction may continue for up to 10 years after treatment. 2. Clinicians may continue to administer endocrine suppressive medical treatment before SRS as this may not affect radiographic control. CONCLUSION: This systematic review provides evidence-based recommendations to guide providers caring for adult patients with FPA when making decisions pertinent to radiosurgery. The CNS Guidelines Committee will continue to pursue timely updates to further improve the care of patients with this diagnosis.